肝臟是體內(nèi)巨噬細(xì)胞無出其右豐富的器官，其中最主要的是定居于肝血竇的庫普弗細(xì)胞（Kupffer cells），占全身巨噬細(xì)胞總量的80%–90%?。肝臟巨噬細(xì)胞，可分為駐留型巨噬細(xì)胞（Kupffer 細(xì)胞）和浸潤型巨噬細(xì)胞，在肝損害時(shí)兩者發(fā)揮協(xié)同作用。庫普弗細(xì)胞是肝臟駐留的組織駐留巨噬細(xì)胞，主要附著于肝血竇內(nèi)皮細(xì)胞之間，直接接觸從門靜脈和肝動(dòng)脈流入的血液，能及時(shí)識(shí)別并清除腸道來源的細(xì)菌、內(nèi)毒素、衰老紅細(xì)胞及免疫復(fù)合物 。多數(shù)庫普弗細(xì)胞起源于胚胎卵黃囊，在肝臟中自我維持；但在損傷或清除后，骨髓來源的單核細(xì)胞會(huì)迅速補(bǔ)充并分化為功能性巨噬細(xì)胞 。這種雙重來源機(jī)制保障了肝臟免疫功能的持續(xù)性。

當(dāng)使用荷蘭Liposoma氯膦酸鹽脂質(zhì)體Clodronate Liposomes尾靜脈注射后，清除效果通常在注射后24–48小時(shí)達(dá)到峰值 。肝臟巨噬細(xì)胞被清除后，骨髓來源的單核細(xì)胞會(huì)及時(shí)補(bǔ)充并分化為新的巨噬細(xì)胞?。新的巨噬細(xì)胞可在?1周左右開始重新出現(xiàn)?，并在后續(xù)幾天內(nèi)逐步恢復(fù)數(shù)量 。這些新補(bǔ)充的巨噬細(xì)胞在表型和功能上可能與原始庫普弗細(xì)胞存在差異，通常表現(xiàn)為更強(qiáng)的促炎潛能或組織修復(fù)能力，具體取決于病理狀態(tài) 。

巨噬細(xì)胞清除劑Clodronateliposomes氯膦酸鹽脂質(zhì)體清除肝臟巨噬細(xì)胞效果時(shí)間動(dòng)態(tài)曲線-免疫組化，可以參考如下數(shù)據(jù)：

A.尾靜脈注射荷蘭Liposoma巨噬細(xì)胞清除劑ClodronateLiposomes（貨號(hào)：C-005），分別于注射后24h，48h，72h取樣肝臟，免疫組化（IHC）檢測肝臟F4/80，0h為注射的對(duì)照試劑ControlLiposomes（貨號(hào)：P-005）。注射后24h，約90%的F4/80陽性肝臟巨噬細(xì)胞被清除，且注射后72h，清除效果仍然顯著。

B.免疫組化染色F4/80陽性區(qū)域占比肝臟的百分比。

論文信息：

論文題目：Macrophage-targeted Mms6 mRNA-lipid nanoparticles promote locomotor functional recovery after traumatic spinal cord injury in mice

期刊名稱：Science Advances

時(shí)間期卷：Vol 11, Issue 13(2025)

在線時(shí)間：2025年3月26日

DOI：10.1126/sciadv.ads2295

產(chǎn)品信息：

貨號(hào)：CP-005-005

規(guī)格：5ml+5ml

品牌：Liposoma

產(chǎn)地：荷蘭

名稱：Clodronate Liposomes&Control Liposomes

辦事處：靶點(diǎn)科技

Clodronate Liposomes氯膦酸鹽脂質(zhì)體在小鼠創(chuàng)傷性脊髓損傷（SCI）模型種清除肝臟和脾臟巨噬細(xì)胞。荷蘭Liposoma巨噬細(xì)胞清除劑ClodronateLiposomes見刊于Science Advances：巨噬細(xì)胞靶向的Mms6 mRNA脂質(zhì)納米顆粒促進(jìn)小鼠創(chuàng)傷性脊髓損傷后的運(yùn)動(dòng)功能恢復(fù)

Liposoma巨噬細(xì)胞清除劑Clodronate Liposomes氯膦酸二鈉脂質(zhì)體清除巨噬細(xì)胞的材料和方法：

Macrophage depletion and evaluation of depletion efficiency

Macrophages were depleted by injection of clodronate-contained liposomes (Clodrosome) into mice (Liposoma B.V., Amsterdam, The Netherlands) according to a previously published protocol (40). C57BL/6J mice were intravenously injected with 0.2 ml of Clodrosome (5 mg/ml). Mice treated with PBS-containing liposomes without clodronate were used as controls. Flow cytometry and immunohistochemistry were used to assess the efficiency of macrophage depletion in the liver and spleen of mice at 0, 24, 48, and 72 hours after Clodrosome treatment using a mouse anti-F4/80 antibody (ab111101, Abcam; 1:100). Then, the optimal timing of maximum depletion was chosen for further study.

巨噬細(xì)胞清除材料和方法文獻(xiàn)截圖：